{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ROS1+Gene+Mutation",
    "query": {
      "condition": "ROS1 Gene Mutation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ROS1+Gene+Mutation&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:38:30.888Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03042221",
      "title": "Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-Small Cell Carcinoma of Lung, TNM Stage 4",
        "Non-Small Cell Lung Cancer",
        "EGFR Gene Mutation",
        "ALK Gene Mutation",
        "ROSE Cluster 1",
        "BRAF V600E"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 100,
      "start_date": "2016-05-10",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-05-22T05:38:30.888Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03042221"
    },
    {
      "nct_id": "NCT04800822",
      "title": "PF-07284892 in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PF-07284892",
          "type": "DRUG"
        },
        {
          "name": "lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "binimetinib",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "encorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2021-03-17",
      "completion_date": "2024-06-19",
      "has_results": false,
      "last_update_posted_date": "2024-10-22",
      "last_synced_at": "2026-05-22T05:38:30.888Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Encinitas, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04800822"
    },
    {
      "nct_id": "NCT05681780",
      "title": "Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Stage IV Non-small Cell Lung Cancer",
        "Recurrent Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Tumor-infiltrating Lymphocytes (TIL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Tumor-infiltrating Lymphocyte Therapy",
          "type": "OTHER"
        },
        {
          "name": "Interleukin-2 (IL2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-03-10",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-05-22T05:38:30.888Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05681780"
    },
    {
      "nct_id": "NCT03944265",
      "title": "Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Activating ALK Gene Mutation Negative",
        "Activating EGFR Gene Mutation Negative",
        "Activating ROS1 Gene Mutation Negative",
        "Health Care Provider",
        "Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Counseling",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Medical Chart Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2019-02-08",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-05-22T05:38:30.888Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03944265"
    },
    {
      "nct_id": "NCT02186821",
      "title": "Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumors With Aberrations in ALK or ROS1"
      ],
      "interventions": [
        {
          "name": "Ceritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2014-09-17",
      "completion_date": "2017-12-13",
      "has_results": true,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-05-22T05:38:30.888Z",
      "location_count": 21,
      "location_summary": "Santa Rosa, California • Denver, Colorado • Greenwood Village, Colorado + 17 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02186821"
    },
    {
      "nct_id": "NCT03049618",
      "title": "Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ALK Gene Mutation",
        "BRAF Gene Mutation",
        "EGFR Gene Mutation",
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic Head and Neck Carcinoma",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "ROS1 Gene Mutation",
        "Stage III Non-Small Cell Lung Cancer",
        "Stage IIIA Non-Small Cell Lung Cancer",
        "Stage IIIB Non-Small Cell Lung Cancer",
        "Stage IV Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant EphB4-HSA Fusion Protein",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2017-03-10",
      "completion_date": "2024-09-04",
      "has_results": true,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-05-22T05:38:30.888Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03049618"
    },
    {
      "nct_id": "NCT01531361",
      "title": "Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "BRAF Gene Mutation",
        "Metastatic Malignant Neoplasm",
        "Recurrent Malignant Neoplasm",
        "Refractory Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2012-02-06",
      "completion_date": "2021-01-13",
      "has_results": false,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-05-22T05:38:30.888Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01531361"
    },
    {
      "nct_id": "NCT02473497",
      "title": "Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "Crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-05-22T05:38:30.888Z",
      "location_count": 17,
      "location_summary": "Aurora, Colorado • St. Petersburg, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02473497"
    },
    {
      "nct_id": "NCT03868423",
      "title": "Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "ALK Fusion Protein Expression",
        "ALK Gene Amplification",
        "ALK Gene Mutation",
        "Locally Advanced Malignant Solid Neoplasm",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Malignant Neoplasm in the Central Nervous System",
        "Metastatic Malignant Solid Neoplasm",
        "ROS1 Fusion Positive",
        "ROS1 Gene Amplification",
        "ROS1 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sameek Roychowdhury",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-03-20",
      "completion_date": "2021-12-30",
      "has_results": false,
      "last_update_posted_date": "2022-02-18",
      "last_synced_at": "2026-05-22T05:38:30.888Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03868423"
    },
    {
      "nct_id": "NCT05370469",
      "title": "Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Cancer",
        "EGFR Gene Mutation",
        "EGFR",
        "ALK Gene Mutation",
        "RET Gene Mutation",
        "MET Gene Mutation",
        "KRAS Mutation-Related Tumors",
        "BRAF",
        "ROS1 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Sensus Smartwatch Application",
          "type": "OTHER"
        },
        {
          "name": "RX Cap",
          "type": "DEVICE"
        },
        {
          "name": "Fitbit Sense",
          "type": "DEVICE"
        },
        {
          "name": "Surveys",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-08-25",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-05-22T05:38:30.888Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05370469"
    }
  ]
}